<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03147027</url>
  </required_header>
  <id_info>
    <org_study_id>15-007</org_study_id>
    <nct_id>NCT03147027</nct_id>
  </id_info>
  <brief_title>Catheter Ablation for Nonsustained Ventricular Tachycardia in Patients With Ischemic Cardiomyopathy</brief_title>
  <acronym>nsVT</acronym>
  <official_title>Catheter Ablation for Nonsustained Ventricular Tachycardia in Patients With Ischemic Cardiomyopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Heinrich-Heine University, Duesseldorf</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Heinrich-Heine University, Duesseldorf</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Despite established implantable cardioverter-defibrillator (ICD) therapy and catheter
      ablation for sustained ventricular tachycardia (VT) in patients with ischemic heart disease
      (IHD) and reduced left ventricular ejection fraction (LVEF), the efficacy of catheter
      ablation in patients with nonsustained VT has been not yet clarified. The incidence of
      appropriate ICD therapy itself has been reported to be a worse prognostic factor in patients
      with reduced LVEF. Therefore theoretically the inhibition of these ventricular incidences can
      result in the prognostic improvement.To suppress ventricular arrhythmias aside from
      antiarrhythmic agents, catheter ablation has been developed prominently in this decade along
      with the technological improvement such as irrigated ablation catheters, three-dimensional
      mapping systems, multi-polar catheters, and image integration system with CT and MRI. The
      rationale of this trial is to study the efficacy of the eradication of arrhythmogenic
      substrate in ischemic cardiomyopathy with reduced LVEF and nonsustained VT on prevention of
      the occurrence of sustained VT/VF and ICD therapies.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 2, 2017</start_date>
  <completion_date type="Anticipated">June 2020</completion_date>
  <primary_completion_date type="Anticipated">May 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>occurrence of sustained VT/VF or ICD therapy</measure>
    <time_frame>time from randomization to occurrence of any sustained VT/VF within 24 months</time_frame>
    <description>occurrence of sustained VT/VF or ICD therapy including ATP and shock</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>survival free from clinical events</measure>
    <time_frame>time from randomization to 24 months</time_frame>
    <description>survival free from clinical events (death, syncope, hospital admission due to cardiac problems, and VT storm, defined as more than three VT episodes in 24 hours)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of appropriate ICD therapies</measure>
    <time_frame>time from randomization to 24 months</time_frame>
    <description>number of appropriate ICD therapies (ATP or shock)</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">72</enrollment>
  <condition>Ventricular Tachycardia</condition>
  <condition>Ischemic Cardiomyopathy</condition>
  <condition>Reduced LVEF</condition>
  <arm_group>
    <arm_group_label>VT ablation group</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>medication group</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>VT ablation</intervention_name>
    <description>Substrate mapping for VT will be performed with the CARTO electroanatomical system.</description>
    <arm_group_label>VT ablation group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>medication</intervention_name>
    <description>medication to prevent sustained VT and ICD therapies</description>
    <arm_group_label>medication group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        patients with nonsustained VT and ischemic cardiomyopathy and reduced LVEF
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  left ventricular ejection fraction (TTE or MRI) ≤40%

          -  diagnosed ischemic heart disease

          -  nonsustained monomorphic VT with more than 5 beats in the record of the implantable
             cardioverter-defibrillator or in any means of electrocardiogram (ECG) including ECG
             monitor and holter monitoring

          -  ICD implantation with primary preventive indication

        Exclusion Criteria:

          -  ICD implantation within 2 months

          -  previously documented sustained VT/VF (over 30 seconds) or adequate ICD shock

          -  no written informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Hisaki Makimoto, MD</last_name>
    <phone>+492118118800</phone>
    <email>hisaki.makimoto@med.uni-duesseldorf.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rabea Wagstaff, MA</last_name>
    <phone>+492118118800</phone>
    <email>rabea.wagstaff@med.uni-duesseldorf.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Division of Cardiology, Pulmonary Disease and Vascular Medicine</name>
      <address>
        <city>Düsseldorf</city>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hisaki Makimoto, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Rabea Wagstaff, M.A.</last_name>
    </contact_backup>
    <investigator>
      <last_name>Hisaki Makimoto, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alexander Fürnkranz, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Patrick Müller, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lukas Clasen, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jan Schmidt, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Muhammed Kurt, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christoph Brinkmeyer, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 5, 2017</study_first_submitted>
  <study_first_submitted_qc>May 9, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 10, 2017</study_first_posted>
  <last_update_submitted>May 23, 2017</last_update_submitted>
  <last_update_submitted_qc>May 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Heinrich-Heine University, Duesseldorf</investigator_affiliation>
    <investigator_full_name>Klinik für Kardiologie, Pneumologie und Angiologie</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>ischemic cardiomyopathy</keyword>
  <keyword>prophylactic ablation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Tachycardia</mesh_term>
    <mesh_term>Tachycardia, Ventricular</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

